Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Conditions

• Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)
• Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)
• Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
• Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
• Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)

Interventions

• BIOLOGICAL: Volrustomig
• DRUG: Cisplatin
• DRUG: Carboplatin
• DRUG: Paclitaxel
• DRUG: 5-FU

Sponsor

AstraZeneca